Melanotan11
MT-II
MT-11 is a synthetic peptide primarily studied for its role in targeting senescent cells—the damaged or “retired” cells that no longer function properly but remain in the body, releasing harmful inflammatory signals. These senescent cells are linked to aging, tissue dysfunction, and chronic diseases. MT-11 belongs to a class of peptides known as senolytics, which are designed to identify and eliminate these dysfunctional cells, allowing healthier, younger cells to thrive. This selective clearing process may help reduce systemic inflammation, improve tissue regeneration, and potentially slow age-related decline.
In early research, MT-11 has shown promise in enhancing cellular turnover, improving skin health, and possibly extending healthy lifespan by promoting a more youthful internal environment. It may also help reduce oxidative stress and support better mitochondrial function, which is essential for energy production and metabolic health. Though still considered experimental and not widely available for clinical use, MT-11 represents a cutting-edge approach to anti-aging medicine, focusing not just on treating symptoms but addressing one of the root causes of aging at the cellular level.
Protocols
1. Skin Tanning & UV Protection
Dosage: 0.25–1 mg per injection, once daily or every other day
Cycle: Initial loading phase (2–3 weeks), then maintenance (1–2 mg per week)
Administration: Subcutaneous (SC) injection, preferably in the evening to minimise nausea
Stacking: Can be combined with moderate sun exposure or tanning beds for enhanced pigmentation
Expected Benefits: Darker, longer-lasting tan, reduced UV damage, increased melanin production
2. Libido & Sexual Enhancement
Dosage: 0.5–1 mg per injection, as needed (1–2 hours before activity)
Cycle: Used on demand or as part of a daily regimen
Administration: SC injection
Stacking: Works well with PT-141 (Bremelanotide) for enhanced libido effects
Expected Benefits: Increased sexual desire, improved erectile function in men, enhanced sensitivity in women
3. Fat Loss & Appetite Suppression
Dosage: 0.5–1 mg per injection, once daily
Cycle: 4–8 weeks, reassess based on results
Administration: SC injection, preferably in the morning or before meals to reduce appetite
Stacking: Can be paired with AOD-9604 or Tesamorelin for improved fat metabolism
Expected Benefits: Decreased appetite, increased fat oxidation, improved body composition
Further reading
Melanotan II primarily functions by stimulating melanocortin receptors, which regulate melanin production, appetite, and sexual function. It was initially researched as a potential sunless tanning agent, but unexpected effects such as spontaneous erections and heightened sexual arousal led to further studies on its role in treating erectile dysfunction and hypoactive sexual desire disorders.
Its ability to stimulate MC4R and MC3R in the brain contributes to appetite suppression and potential weight loss benefits. Users often report reduced cravings and lower caloric intake when using Melanotan II, making it an attractive option for those looking to manage body composition. However, its effects on metabolism and weight loss are secondary to its primary function as a melanocortin agonist.
Despite its benefits, Melanotan II is not without risks. Common side effects include nausea, flushing, increased freckles, and potential darkening of existing moles. Some users also experience fatigue or mild headaches. A more serious concern is priapism (prolonged erections), which can occur with higher doses and requires medical attention if prolonged.
Due to limited clinical research and regulatory concerns, Melanotan II remains unapproved for medical use in many countries. However, it continues to be used in the fitness and cosmetic communities for its tanning and libido-enhancing properties.
References
- Hadley, M. E., et al. (1996). "Melanotan II: A cyclic melanotropic peptide with potent tanning activity in humans." Annals of the New York Academy of Sciences, 885, 477–481.
Wessells, H., et al. (2000). "Melanocortin receptor agonists: The next generation of therapies for erectile dysfunction?" International Journal of Impotence Research, 12(S4), S64–S69.
Sharma, G., et al. (2019). "Melanotan peptides: Potential role in obesity treatment." Obesity Reviews, 20(5), 675–685.
Dorr, R. T., et al. (2004). "The pharmacokinetics and safety of Melanotan II in human subjects." Clinical Pharmacology & Therapeutics, 76(1), 66–73.
Shadiack, A. M., et al. (2007). "Melanocortins in sexual function and obesity: A review of clinical potential." Neuropeptides, 41(5), 287–293.